MedTrace Logo

Effect of Homocysteine and Asymmetric Dimethylarginine on Cardiovascular Events in Hemodialysis Patients

NCT00161369 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2005-10-21

No results posted yet for this study

Summary

Homocysteine (Hcy) and asymmetric dimethylarginine (ADMA) have recently been recognized as potential risk factors for atherosclerosis in the general population, and the metabolism of each of these substances seems to be closely related. This study investigates the association between these substances, and whether elevated serum levels of Hcy and ADMA would be related to a high risk of atherosclerosis and cardiovascular events in maintenance hemodialysis (HD) patients.

Conditions

Sponsors & Collaborators

  • Maruyama Memorial General Hospital

    collaborator OTHER

  • Hamamatsu University

    collaborator OTHER

  • University of Shizuoka

    lead OTHER

Principal Investigators

  • Hiromichi Kumagai, MD · University of Shizuoka

Eligibility

Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-04-30
Completion
2005-03-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00161369 on ClinicalTrials.gov